Compare Regeneron Pharmaceuticals Inc (REGN) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Nuscale Power Corporation trades at $10.82 (market cap $4.59B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 18.2× Nuscale Power Corporation's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| REGN | SMR | |
|---|---|---|
Market Cap | $83.43B | $4.59B |
Sector | Health | Utilities |
52-Week High | $852.03 | $53.43 |
52-Week Low | $555.51 | $7.59 |
Enterprise Value | $78.14B | $3.52B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
SMR stock surged 15.32% to $11.18, showing strong bullish momentum with technical indicators supporting the uptrend. The company maintains a substantial cash position of $1.9 billion despite significant operating losses and negative profit margins. Recent news highlights NuScale's positioning in the nuclear energy sector, particularly for AI power demands, though the company remains years away from commercial deployment.
The outlook remains speculative with Wall Street divided - 50% of analysts recommend Buy with a $11.25 consensus target. Key risks include cash burn acceleration, lack of firm commercial contracts, and execution challenges in bringing small modular reactors to market. The stock offers high-risk/high-reward potential for investors betting on nuclear energy adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
